Interpreting Concentrations Relative to a Target

Why a Target Comparison Needs Context

A concentration can be numerically below a stated range without being meaningfully “too low,” or numerically inside a range without establishing that the patient’s exposure is appropriate. Interpretation depends first on what the target describes: a trough concentration, a peak, an AUC, or another measure; which analyte is measured; and what clinical purpose the target is intended to serve. The sampling time and assay uncertainty then determine how confidently the result can be placed relative to that target.

The earlier material on recording sample time, sampling around dosing, analytical uncertainty, and minimum interpretation metadata supplies the relevant checks. Here the task is to connect those checks to a target classification. This is a classification of a measured result relative to a stated target, not by itself a diagnosis or a dosing instruction.

Definition: A target is a stated concentration or exposure criterion, expressed for a specified analyte, metric, unit, and clinical purpose. A two-sided target is written \([L,U]\), where \(L\) is the lower boundary and \(U\) is the upper boundary. A result is below, within, or above by point estimate when its value is, respectively, less than \(L\), between \(L\) and \(U\), or greater than \(U\). These labels are clinically interpretable only if the measured quantity is comparable to the target.

Establish That the Comparison Is Valid

Before comparing numbers, establish that they refer to the same thing. Check the drug and analyte, units, and exposure metric. A parent-drug concentration cannot automatically be judged against a metabolite target. A single concentration cannot be compared directly with an AUC target, which summarizes exposure over time. Convert units only when the conversion is unambiguous and preserve the target’s intended metric.

Next check sampling time against the target definition. A trough target applies to a sample collected at the specified point in the dosing interval; a sample collected during absorption or soon after an infusion may not represent that trough. Whether the patient is at steady state, has taken doses as intended, or has had a recent dose delay can also affect whether the target is applicable. If the target is defined for steady-state dosing, a pre-steady-state sample should not be treated as though it were a steady-state trough simply because it was collected before a dose.

Finally, identify the target’s clinical purpose. A range may be intended to support efficacy while limiting toxicity, but its boundaries are not universal biological cutoffs. Some targets are population-based guides; others are selected for a particular patient, indication, or treatment objective. A one-sided threshold may be more appropriate than a two-sided range when the purpose is, for example, to avoid concentrations above a safety limit. The intended consequence of being near or beyond a boundary affects how carefully uncertainty should be considered; it does not change the arithmetic of the comparison.

Practical rule: Do not classify a value until the target and the result match in analyte, units, exposure metric, and relevant sampling conditions. If any match is uncertain, state that limitation rather than presenting a definitive below/within/above label.

Point Estimates and Assay Uncertainty

A simple comparison uses the reported result \(y\) as though it were the concentration at the sampling time. This produces a point-estimate classification: compare \(y\) with \(L\) and \(U\). It is easy to communicate, but it does not show how much analytical uncertainty could change the label near a boundary.

If the laboratory provides an analytical standard error \(SE\), one common approximation assumes that the reported result is unbiased and that analytical error is normally distributed with known \(SE\). Under that measurement model, an approximate 95% interval for the concentration at the sampled time is \(y \pm 1.96SE\). The interval summarizes analytical uncertainty under those assumptions; it does not include all sources of uncertainty, such as an incorrect sample time, within-patient variation, or uncertainty in the target itself.

\text{Approximate 95\% analytical interval} = [y-1.96SE,\;y+1.96SE]

An uncertainty-aware classification compares the whole interval with the target. If the interval lies entirely below \(L\), the result is clearly below the target given the stated analytical model. If it lies entirely within \([L,U]\), it is clearly within by that criterion. If it lies entirely above \(U\), it is clearly above. If it crosses a boundary, the point estimate still has a label, but assay uncertainty does not support a confident classification on that side of the boundary.

\begin{aligned} y+1.96SE < L &\quad \Rightarrow \quad \text{clearly below},\\ y-1.96SE \geq L \text{ and } y+1.96SE \leq U &\quad \Rightarrow \quad \text{clearly within},\\ y-1.96SE > U &\quad \Rightarrow \quad \text{clearly above}. \end{aligned}

These rules use a 95% interval as a practical uncertainty summary, not as a guarantee that the unknown concentration lies in the interval. Under repeated measurement with the stated assumptions, intervals constructed this way would cover the fixed concentration about 95% of the time. When the interval overlaps a boundary, say “the point estimate is below, but the analytical interval overlaps the target boundary,” rather than forcing an unqualified label.

Worked Classifications

Worked Example: A Result Clearly Below a Trough Target

Suppose a hypothetical drug has a stated steady-state trough target of 5.0–10.0 mg/L. A pre-dose sample is collected immediately before the next dose after the intended regimen has been followed to steady state. The reported concentration is 4.2 mg/L, and the laboratory reports an analytical \(SE\) of 0.20 mg/L. Assume the assay is unbiased, its analytical errors are approximately normal, and the reported \(SE\) applies to this result.

The point estimate is below the lower boundary because \(4.2 < 5.0\) mg/L. Its approximate 95% analytical interval is:

4.2 \pm 1.96(0.20) =4.2\pm0.392 =[3.808,\;4.592]\ \text{mg/L}.

The upper end, 4.592 mg/L, is still below 5.0 mg/L. Thus the result is clearly below this stated trough target relative to the specified analytical uncertainty. This conclusion assumes the target applies to this patient and regimen; it does not alone establish why the concentration is low or what dose change, if any, is appropriate.

Worked Example: A Point Estimate Below the Boundary but Uncertain

In a second hypothetical case, a correctly timed trough is reported as 4.8 mg/L against the same 5.0–10.0 mg/L target. The analytical \(SE\) is 0.25 mg/L. Assume the same unbiased normal-error model and that the sample timing and target are applicable.

By point estimate, \(4.8 < 5.0\) mg/L, so the value is below. But the approximate 95% analytical interval is:

4.8 \pm 1.96(0.25) =4.8\pm0.490 =[4.310,\;5.290]\ \text{mg/L}.

This interval crosses the lower target boundary. The defensible statement is that the point estimate is slightly below target, while analytical uncertainty does not clearly distinguish a concentration below the boundary from one at or above it. It would be incorrect to call the result confidently below, or to report it as clearly within merely because part of the interval is within the target.

Worked Example: A One-Sided Safety Threshold

A hypothetical monitoring protocol specifies that a peak concentration should not exceed 20 mg/L. The purpose is to avoid concentrations above that threshold; there is no lower boundary in this criterion. A correctly timed peak is 18.9 mg/L with analytical \(SE=0.40\) mg/L. Assume unbiased normal analytical error and a peak sample collected at the time specified by the protocol.

The point estimate is under the threshold: \(18.9 < 20\) mg/L. The approximate 95% analytical interval is:

18.9\pm1.96(0.40) =18.9\pm0.784 =[18.116,\;19.684]\ \text{mg/L}.

The interval’s upper end is below 20 mg/L, so the result is below the one-sided threshold given the analytical uncertainty model. It should not be called “within the 5–10 mg/L trough range,” because it is a peak and the applicable criterion is a one-sided peak threshold. The clinical purpose and sampling definition determine the meaningful comparison.

Justification for the Uncertainty Rule

The interval comparison follows directly from the measurement model. Let \(C\) denote the fixed concentration at the time of sampling and suppose \(Y=C+\varepsilon\), where \(\varepsilon\sim N(0,SE^2)\). Then the standardized measurement error \((Y-C)/SE\) follows a standard normal distribution. Approximately 95% of standard normal values lie between \(-1.96\) and \(1.96\). Rearranging that event gives an interval for \(C\):

P\left(-1.96 \leq \frac{Y-C}{SE}\leq1.96\right)\approx0.95 \quad\Longleftrightarrow\quad C\in[Y-1.96SE,\;Y+1.96SE].

For the observed result \(y\), if the interval’s upper endpoint is less than \(L\), then every concentration represented by this interval is below the lower boundary. If its lower endpoint exceeds \(U\), the interval is wholly above the upper boundary. If both endpoints fall within the target, it is wholly within. Overlap means the interval-based evidence does not settle the side of that boundary. This reasoning depends on the stated measurement model and does not turn an analytical interval into a clinical decision rule.

Diagnostics, Alternatives, and Limitations

Several warning signs should interrupt a routine classification. A sample time that is unknown or inconsistent with the target, a recent missed dose when the target assumes regular dosing, an unexpected analyte, or a unit mismatch can make the comparison invalid. A result close to a boundary relative to its analytical \(SE\) should be reported with that uncertainty. If the laboratory reports a coefficient of variation rather than an \(SE\), do not insert it directly into the interval formula: first confirm what the measure represents and how it applies to the observed concentration. If analytical error is appreciably non-normal or uncertainty is reported asymmetrically, a symmetric \(y\pm1.96SE\) interval may be unsuitable.

Direct point comparison is the simplest alternative: it is transparent and may be adequate when the result is far from the boundaries and measurement uncertainty is small. The uncertainty-interval approach makes the boundary ambiguity explicit, but addresses analytical uncertainty only. A pharmacokinetic model may be more appropriate when the intended comparison concerns an unobserved exposure measure, such as AUC, or when sampling time differs from the target definition; however, that approach requires a suitable model and additional assumptions. Neither method resolves an inappropriate target or an unrepresentative sample.

Targets are not always sharp biological divisions. A small numerical difference across a boundary may not imply a sudden change in benefit or risk, and a concentration within a reference range does not guarantee a desired clinical outcome. This tutorial’s classification should therefore be reported alongside the target definition, relevant timing, uncertainty, and clinical purpose. Whether a concentration and a patient’s response tell different stories is a separate interpretive question.

Common Mistakes

Comparing unlike quantities. A peak is not a trough, and a concentration is not an AUC. Match metric, analyte, units, and timing first.
Treating a borderline point estimate as certain. A result just below \(L\) can have an analytical interval that crosses \(L\). Report both the point classification and the uncertainty.
Calling any value inside a range clinically adequate. The target’s purpose and applicability matter; the label alone does not establish efficacy or safety.
Using analytical uncertainty as if it covered every source of uncertainty. The assay interval does not correct for mistimed sampling, dose history, or within-patient variability.
Forcing a two-sided label onto a one-sided criterion. If the clinical criterion is “not above \(U\),” interpret it as a threshold rather than inventing a lower boundary.

Key takeaway: A defensible target interpretation starts by validating the comparison, then distinguishes the point estimate from what assay uncertainty supports. State the target’s purpose and avoid treating a classification as a dosing decision or proof of clinical outcome.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions.

A hypothetical trough target is 8–12 mg/L. A correctly timed result is 7.4 mg/L with \(SE=0.20\) mg/L. Using an approximate 95% analytical interval, is it clearly below?
A result is reported inside a target range, but it was collected during absorption when the target is defined for a pre-dose trough. What is the main interpretive problem?
A hypothetical concentration is 9.8 mg/L, \(SE=0.30\) mg/L, and the target is 10–15 mg/L. Give the point-estimate classification and explain what the interval adds.
A protocol states only that a peak should be below 25 mg/L. Why is it not appropriate to describe the result as below, within, or above a two-sided range unless a lower boundary is also specified?

Solutions. (1) The interval is \(7.4\pm1.96(0.20)=7.4\pm0.392=[7.008,7.792]\) mg/L. Its upper end is below 8 mg/L, so it is clearly below given the analytical model. (2) The measured value is not directly comparable to a trough target; the timing mismatch must be resolved or explicitly acknowledged before classification. (3) The point estimate is below because \(9.8<10\) mg/L. Its interval is \(9.8\pm1.96(0.30)=[9.212,10.388]\) mg/L, which crosses 10 mg/L, so analytical uncertainty does not support a clear below-boundary classification. (4) The criterion has one boundary and a specific safety purpose. Without a defined lower boundary, “within” a two-sided range would add a criterion not present in the protocol; interpret whether the result is below or above the stated threshold instead.